ENO2 and neoplasm: By combining these 8 lung cancer autoantibodies with the 4 tumor markers (CYFRA21-1, CEA, SCCA, and NSE) in the test set, the sera from patients with early-stage lung cancer and the sera from patients with benign lung nodules were better differentiated.